IP Library Granted Patent US 10,624,781
Granted Patent B2
US 10,624,781 · App. 14/992,975 · Granted Apr 21, 2020

Micro-droplet delivery device and methods

Inventor: Yehuda Ivri (Newport Beach, CA)
Assignee: Kedalion Therapeutics, Inc.
A61F9/0008F04B43/046
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,624,781
App. No.
14/992,975
Granted
Apr 21, 2020
Kind
B2
Abstract

Micro-droplet delivery devices and methods are described where the device may comprise a piezoelectric actuator having a piezoelectric chip that is operatively coupled to a drug package under a preloading force. The actuator is configured to generate an acoustic pressure within the drug package to dispense droplets of an agent from an aperture, e.g., to the corneal surface of the eye. The piezoelectric actuator can be coupled or decoupled from the drug package.

Claims (32)

1. A system for emitting a fluid, comprising:

(a) an actuator having a contact portion; and

(b) a drug package comprising:

(i) a fluid reservoir near or at one end of the drug package;

(ii) an elongated conduit extending from the fluid reservoir and terminating in a tip section having a single aperture, wherein the elongated conduit comprises an internal fluid channel in fluid communication with the interior of the fluid reservoir and the aperture;

(iii) an acoustic cavity comprising a cylindrical chamber having an upper circular face sealed by a thin-wall membrane, wherein the acoustic cavity is positioned along the internal fluid channel between the fluid reservoir and the tip section; and

(iv) a fluid ophthalmic drug composition present in the fluid reservoir, acoustic cavity and internal fluid channel,

wherein the drug package is removably separable from the actuator and is also positionable to align thin-wall membrane of the acoustic cavity with the contact portion of the actuator such that displacement induced on the external surface of the thin-wall membrane by the contact portion of the actuator transmits one or more acoustic pulses through the fluid ophthalmic drug composition in the internal fluid channel to eject fluid through the aperture to produce a stream.

2. The system of claim 1 wherein the actuator comprises a piezoelectric chip.

3. The system of claim 2 wherein the piezoelectric chip is configured to have a displacement of 1-5 microns.

4. The system of claim 1 wherein the acoustic cavity further comprises a concave surface opposite the upper surface.

5. The system of claim 4 wherein a distance between the fluid reservoir and the acoustic cavity is about 5-15 mm.

6. The system of claim 4 wherein a distance between the acoustic cavity and aperture is about 30-60 mm.

7. The system of claim 4 further comprising a restriction positioned along the conduit between the acoustic cavity and the fluid reservoir to restrict a propagation of acoustic pressure waves into the fluid reservoir.

8. The system of claim 4 wherein the acoustic cavity has a volume of 30-100 μL.

9. The system of claim 1 wherein the fluid reservoir has a volume of about 1000 μL.

10. The system of claim 1 wherein the aperture has a diameter of 80-120 micron.

11. The system of claim 1 wherein the actuator is programmed to dispense the fluid through the aperture at a frequency of 10 Hz-30 KHz.

12. The system of claim 1 wherein the fluid is ejected as a stream of micro-droplets.

13. The system of claim 12 wherein the actuator is programmed to eject the fluid in a single drop format to produce a stream of micro-droplets.

14. The system of claim 12 wherein the micro-droplets range in volume from 100 pL to 1000 pL.

15. The system of claim 1 wherein the actuator is programmed to eject the fluid as a stream of micro-droplets at pre-determined time intervals.

16. The system of claim 1 further comprising an eyeglass frame upon which the system is attached.

17. The system according to claim 16 wherein the system is attached to an earpiece of the eyeglass frame.

18. The system according to claim 17 wherein the system is attached to the earpiece in a manner such that the drug package reaches a lens of the eyeglass frame and the tip section is bent sideways such that the aperture is oriented toward the eye.

19. A method of emitting a fluid, comprising:

aligning an actuator having a contact portion with a drug package comprising an aperture at a first end comprising a tip section of the drug package and a fluid reservoir near or at a second end of the drug package, wherein the fluid reservoir contains a volume of a fluid ophthalmic drug composition and the drug package is removably separable from the actuator; and

displacing the contact portion of the actuator on the external surface of the drug package to cause one or more acoustic pulses to be transmitted through the fluid ophthalmic drug composition in the drug package such that fluid is ejected through the aperture as a stream;

wherein the actuator is attached to an earpiece of an eyeglass frame and the drug package reaches a lens of the eyeglass frame and the tip section is bent sideways such that the aperture is oriented toward the eye.

20. The method of claim 19 further comprising removing the drug package from the actuator.

21. The method of claim 19 wherein displacing comprises actuating a piezoelectric chip which displaces the contact portion.

22. The method of claim 21 wherein displacing comprises displacing the contact portion 1-5 microns.

Assignments (8)
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (066694/0131) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072460/0655 →
PATENT SECURITY AGREEMENT Recorded Jul 1, 2025
From: BAUSCH & LOMB INCORPORATED; ALDEN OPTICAL LABORATORIES, INC.; BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 071773/0871 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 29, 2024
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 066707/0684 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 27, 2024
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 066694/0131 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2023
From: NOVARTIS AG
To: BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 065531/0583 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNMENT AGREEMENT PREVIOUSLY RECORDED ON REEL 062116 FRAME 0917. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 10, 2023
From: KEDALION THERAPEUTICS, INC.
To: NOVARTIS AG
Reel/Frame 064237/0507 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2022
From: KEDALION THERAPEUTICS, INC.
To: NOVARTIS AG
Reel/Frame 062116/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2016
From: IVRI, YEHUDA; TOPNOTE, INC.
To: KEDALION THERAPEUTICS, INC.
Reel/Frame 039136/0444 →
Continuity (2)
Provisional Application 62125073 · Jan 12, 2015
Related Publication 20160199225A1 · Jul 14, 2016
Cited By (12)
US 12,186,234 US 12,213,912 US 12,290,471 US 12,290,472 US 12,295,881 US 12,303,427 US 12,350,194 US 12,409,063 US 12,453,651 US 12,458,532 US 12,496,218 US 12,611,326